From a broader perspective, GLP-1 therapies represent a shift in how obesity and metabolic disorders are treated
Obesity, particularly central or abdominal obesity, increases insulin resistance, thereby making it difficult for the body to regulate blood sugar levels
In addition, GLP-1/glucagon and GLP-1/GIP dual receptor agonists and GLP-1/GIP/glucagon triple receptor agonists have shown the potential to reduce blood glucose levels and body weight through their effects on islets and peripheral tissues, improving beta cell function and stimulating energy expenditure
Understanding the process of weaning off tirzepatide or adjusting doses downward becomes relevant here
Saturday afternoons heading north from Tijuana can mean 2-3 hour waits
For instance, insulin and sulfonylureas, the usual treatments of type 2 diabetes